Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several mechanistic and efficacy claims align with the provided label excerpts (BH4 synthetic form, PAH cofactor, reduced blood Phe). However, multiple claims are not supported by the provided label text, including PAH “increased production,” FDA approval year/MHPH specificity, cognitive/behavior/quality-of-life outcomes, diet normalization, manufacturer marketing attribution, and patent expiration.
Category Scores
Accurate Statements
Sapropterin is a synthetic form of tetrahydrobiopterin (BH4).
Supported by 11 DESCRIPTION and 12.1 Mechanism of Action.
Tetrahydrobiopterin (BH4) is a co-factor for the enzyme phenylalanine hydroxylase (PAH).
Supported by 12.1 Mechanism of Action.
Sapropterin decreases blood levels of phenylalanine (Phe).
Supported by 1 INDICATIONS AND USAGE and 12.2 Pharmacodynamics and reflected in 14 CLINICAL STUDIES.
In patients with mild hyperphenylalaninemia (MHPH), sapropterin reduces blood levels of Phe.
Not supported by the provided label excerpts; included here only if interpreted broadly from the presence of a general blood Phe-lowering indication. (Overall evaluated as unsupported in findings.unupportedStatements.)
Unsupported Statements
Sapropterin increases the production of phenylalanine hydroxylase (PAH).
12.1 describes activation of residual PAH and improved oxidative metabolism leading to decreased Phe, but does not state increased PAH production.
Sapropterin was approved by the US Food and Drug Administration (FDA) in 2007 for the treatment of PKU in patients with mild hyperphenylalaninemia (MHPH).
Provided label excerpts do not include an approval year or the specific term MHPH.
In patients with mild hyperphenylalaninemia (MHPH), sapropterin reduces blood levels of Phe.
Provided label excerpts do not mention MHPH.
Sapropterin improves cognitive function in patients with PKU.
No cognitive-function claim is present in the provided label sections.
Sapropterin improves behavior in patients with PKU.
No behavior claim is present in the provided label sections.
Sapropterin increases the quality of life for patients with PKU.
No quality-of-life claim is present in the provided label sections.
Sapropterin allows patients with PKU to eat a more normal diet.
1 INDICATIONS AND USAGE states it is to be used in conjunction with a Phe-restricted diet; it does not support “more normal diet.”
Sapropterin is marketed under the brand name Kuvan by BioMarin Pharmaceutical Inc.
The provided label excerpts show the brand name KUVAN but do not include manufacturer/marketing attribution.
The patent for sapropterin is set to expire in 2025.
No patent or expiration information is present in the provided label excerpts.
Contradictions
Important Omissions
Contraindications, boxed warnings, warnings/precautions, drug interactions, adverse reactions, monitoring, administration instructions, and storage/handling were not provided, so safety-critical alignment cannot be fully assessed for the listed claims.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported claims (e.g., diet normalization and specific clinical outcomes like cognition/behavior/quality of life) could mislead interpretation of expected benefits. However, no direct contraindication/warning misstatements were identified from the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple efficacy/benefit and contextual claims are not supported by the provided prescribing-information excerpts.
Suggested Improvement
Restrict claims to label-supported points in the provided sections: BH4 synthetic form, BH4 as PAH cofactor, and reduction of blood Phe in BH4-responsive PKU/HPA patients used with a Phe-restricted diet. Remove or re-verify unsupported claims about PAH “production,” FDA approval year/MHPH, cognitive/behavioral/quality-of-life outcomes, diet normalization, manufacturer attribution, and patent expiration.